British Gynaecological Cancer Society and British Menopause Society guidelines: Management of menopausal symptoms following treatment of gynaecological cancer.
Alexandra Taylor, Kathryn Clement, Timothy Hillard, Jenifer Sassarini, Nithya Ratnavelu, Holly Baker-Rand, Rebecca Bowen, Melanie C Davies, Katherine Edey, Andreia Fernandes, Sadaf Ghaem-Maghami, Nana Gomes, Sarah Gray, Eluned Hughes, Anna Hudson, Ranjit Manchanda, Kristyn Manley, Shibani Nicum, Andrew Phillips, Alison Richardson, Jo Morrison
{"title":"British Gynaecological Cancer Society and British Menopause Society guidelines: Management of menopausal symptoms following treatment of gynaecological cancer.","authors":"Alexandra Taylor, Kathryn Clement, Timothy Hillard, Jenifer Sassarini, Nithya Ratnavelu, Holly Baker-Rand, Rebecca Bowen, Melanie C Davies, Katherine Edey, Andreia Fernandes, Sadaf Ghaem-Maghami, Nana Gomes, Sarah Gray, Eluned Hughes, Anna Hudson, Ranjit Manchanda, Kristyn Manley, Shibani Nicum, Andrew Phillips, Alison Richardson, Jo Morrison","doi":"10.1177/20533691241286666","DOIUrl":null,"url":null,"abstract":"<p><p>These guidelines have been developed jointly by the British Gynaecological Cancer Society and British Menopause Society to provide information for all healthcare professionals managing women treated for gynaecological cancer. Menopausal symptoms can have a significant impact on quality of life for women. Cancer therapies, including surgery, pelvic radiotherapy, chemotherapy and endocrine therapy, can all affect ovarian function. The benefits and risks of using hormone replacement therapy are considered by cancer type with guidance on the type of HRT and optimal time of commencement after cancer treatment. Vaginal estrogens can be very effective for improving urogenital symptoms and are safe for the majority of women, including those for whom systemic HRT is contraindicated with rare exceptions. Alternative options to HRT are reviewed including pharmacological and non-pharmacological approaches.</p>","PeriodicalId":52104,"journal":{"name":"Post reproductive health","volume":" ","pages":"256-279"},"PeriodicalIF":0.0000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Post reproductive health","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/20533691241286666","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/10/11 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
These guidelines have been developed jointly by the British Gynaecological Cancer Society and British Menopause Society to provide information for all healthcare professionals managing women treated for gynaecological cancer. Menopausal symptoms can have a significant impact on quality of life for women. Cancer therapies, including surgery, pelvic radiotherapy, chemotherapy and endocrine therapy, can all affect ovarian function. The benefits and risks of using hormone replacement therapy are considered by cancer type with guidance on the type of HRT and optimal time of commencement after cancer treatment. Vaginal estrogens can be very effective for improving urogenital symptoms and are safe for the majority of women, including those for whom systemic HRT is contraindicated with rare exceptions. Alternative options to HRT are reviewed including pharmacological and non-pharmacological approaches.
期刊介绍:
Post Reproductive Health (formerly Menopause International) is a MEDLINE indexed, peer reviewed source of news, research and opinion. Aimed at all those involved in the field of post reproductive health study and treatment, it is a vital resource for all practitioners and researchers. As the official journal of the British Menopause Society (BMS), Post Reproductive Health has a broad scope, tackling all the issues in this field, including the current controversies surrounding postmenopausal health and an ageing and expanding female population. Initially this journal will concentrate on the key areas of menopause, sexual health, urogynaecology, metabolic bone disease, cancer diagnosis and treatment, recovering from cancer, cardiovascular disease, cognition, prescribing, use of new hormone therapies, psychology, the science of ageing, sociology, economics, and quality of life. However as a progressive and innovative journal the Editors are always willing to consider other areas relevant to this rapidly expanding area of healthcare.